A pharmacogenetic basis for the safe and effective use of azathioprine and other thiopurine drugs in dermatologic patients
- 31 January 1995
- journal article
- review article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 32 (1) , 114-116
- https://doi.org/10.1016/0190-9622(95)90195-7
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- 6-Thioguanine treatment of psoriasis: Experience in 81 patientsJournal of the American Academy of Dermatology, 1994
- Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipientThe Lancet, 1993
- Human liver thiopurine methyltransferase pharmacogeneticsPharmacogenetics, 1992
- THE IMPORTANCE OF THIOPURINE METHYLTRANSFERASE ACTIVITY FOR THE USE OF AZATHIOPRINE IN TRANSPLANT RECIPIENTS1Transplantation, 1992
- Azathioprine in dermatologyJournal of the American Academy of Dermatology, 1991
- Azathioprine. An effective, corticosteroid-sparing therapy for patients with recalcitrant cutaneous lupus erythematosus or with recalcitrant cutaneous leukocytoclastic vasculitisArchives of Dermatology, 1991
- Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukaemiaThe Lancet, 1990
- Childhood leukaemia: a relationship between intracellular 6‐ mercaptopurine metabolites and neutropenia.British Journal of Clinical Pharmacology, 1983
- AzathioprineInternational Journal of Dermatology, 1981
- Human erythrocyte thiopurine methyltransferase: Radiochemical microassay and biochemical propertiesClinica Chimica Acta; International Journal of Clinical Chemistry, 1978